October 13, 2018

HEPA: Hepion Pharmaceuticals, Inc. Stock

by Wilton Risenhoover

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M)	4.30
Enterprise Value ($M)	8.43
Book Value ($M)	-1.86
Book Value / Share	-0.17
Price / Book	-2.27
NCAV ($M)	-1.86
NCAV / Share	-0.17
Price / NCAV	-2.27

Profitability (mra)
Return on Invested Capital (ROIC)	-12.73
Return on Assets (ROA)	-0.83
Return on Equity (ROE)	-1.75

Liquidity (mrq)
Quick Ratio	0.51
Current Ratio	0.51

Balance Sheet (mrq) ($M)
Current Assets	1.61
Assets	1.61
Liabilities	3.48
Debt	n/a
Equity	n/a

Income Statement (mra) ($M)
Revenue	0.00
Operating Income	-19.35
Net Income	-13.19
Earnings Per Share Basic And Diluted	n/a
Earnings Per Share Diluted	n/a
Earnings Per Share Basic	n/a

Cash Flow Statement (mra) ($M)
Cash From Operations	-18.22
Cash from Investing	-0.60
Cash from Financing	4.35
(click for more detail)

File Date	Form	Activist 13D/G Investors	Ownership (%)	Change (%)
01-24	13G	Bigger Capital Fund L P	9.99
11-14	13G/A	Armistice Capital, Llc	4.99	-27.14

Top 13F Investors	Shares (1000)	Change (%)	Value ($1000)	Change (%)
(click for more detail)

Date	Insider Trades	Code	Shares	Value
(click for more detail)

File Date	Form	SEC Filings
2025-04-08	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the year ended December 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 O
2025-01-13	10-K/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 2)
2024-11-14	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2024 ☐ TRANSITION REPORT PURSUANT
2024-08-13	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2024 ☐ TRANSITION REPORT PURSUANT TO S
2024-06-25	10-K/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A
2024-05-21	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2024 o TRANSITION REPORT PURSUANT TO
(click for more detail)

Short Volume
Market Date	Short Volume	Total Volume	Short Volume Ratio
2025-05-09	123,865	844,592	14.67
2025-05-08	371,199	1,921,155	19.32
2025-05-07	4,675,081	12,386,355	37.74
2025-05-06	1,028,852	3,228,533	31.87
2025-05-05	1,072,862	2,749,923	39.01
(click for more detail)

Similar Companies
GTBP – GT Biopharma, Inc.	GYRE – Gyre Therapeutics, Inc.
HCWB – HCW Biologics Inc.	HOOK – HOOKIPA Pharma Inc.
HOTH – Hoth Therapeutics, Inc.

Financial data and stock pages provided by
Fintel.io

Related